{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:29Z","timestamp":1787019569053,"version":"build-2736575974"},"reference-count":24,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with primary refractory or relapsed (R\/R) MYC-driven aggressive B-cell lymphomas, such as Burkitt lymphoma (BL), plasmablastic lymphoma (PBL), and double-hit lymphoma (DHL)\/triple-hit lymphoma (THL), have a dismal prognosis with few survivors. The deregulated MYC protein drives proliferation with dependence on tricarboxylic acid cycle intermediates as biosynthetic precursors. Devimistat disrupts mitochondrial production of adenosine triphosphate and biosynthetic intermediates. We conducted a phase 2 trial to explore the efficacy of devimistat in R\/R-BL, R\/R-PBL, and R\/R-DHL, administered daily for 5 days every 14 days for 2 cycles, followed by maintenance for 5 days every 21 days until progression, toxicity, or transplant. No responses were seen in the 2 enrolled patients with R\/R-PBL and 9 with R\/R-DHL\/THL. Among the 13 patients with R\/R-BL, 2 had a complete response (CR), resulting in a CR rate (CRR) of 15%, whereas the others experienced rapid disease progression. The median follow-up time for patients with R\/R-BL was 1 month (range, 0-47). Among the 2 patients with R\/R-BL CR, the response duration was 8 months in 1 and ongoing at the time of data cutoff, 17 months after study entry. Overall, 3 patients had grade 3 events at least possibly related to the study drug: neutropenia, thrombocytopenia, headache, noncardiac chest pain, and increase of troponin. Considering the dismal prognosis of R\/R MYC-driven aggressive B-cell lymphomas with the current standard of care and low CRR with devimistat, efforts should be made to improve the outcome of these malignancies with their first line of therapy and explore novel therapies in the R\/R setting. This trial was registered at www.ClinicalTrials.gov as #NCT03793140.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016168","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:03:52Z","timestamp":1752786232000},"page":"5556-5563","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-3629","authenticated-orcid":false,"given":"Raphael","family":"Steiner","sequence":"first","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Nikolaenko","sequence":"additional","affiliation":[{"name":"3Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Nair","sequence":"additional","affiliation":[{"name":"4Division of Cancer Medicine, Department of Lymphoma - Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-2698","authenticated-orcid":false,"given":"Venkatraman","family":"Seshan","sequence":"additional","affiliation":[{"name":"5Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"3Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-5710","authenticated-orcid":false,"given":"Niloufer","family":"Khan","sequence":"additional","affiliation":[{"name":"3Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"6Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6399-2006","authenticated-orcid":false,"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"7Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Owens","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9211-1768","authenticated-orcid":false,"given":"Ildefonso Ismael","family":"Rodriguez Rivera","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"8Texas Oncology and New Experimental Therapeutics LLC, Irving, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Straus","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1186-6948","authenticated-orcid":false,"given":"Timothy S.","family":"Pardee","sequence":"additional","affiliation":[{"name":"9Department of Cancer Medicine, Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Luther","sequence":"additional","affiliation":[{"name":"10Cornerstone Pharmaceuticals, Cranbury, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Saboukoulou","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Win Su","family":"Thet","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Vemuri","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4898","authenticated-orcid":false,"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"6","key":"2025111014270114900_bib1","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"suppl 1","key":"2025111014270114900_bib2","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S2152-2650(20)30455-9","article-title":"Burkitt lymphoma - subtypes, pathogenesis, and treatment strategies","volume":"20","author":"Noy","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2025111014270114900_bib3","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.24720","article-title":"Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia\/lymphoma","volume":"92","author":"Short","year":"2017","journal-title":"Am J Hematol"},{"issue":"suppl_1","key":"2025111014270114900_bib4","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1182\/blood-2019-131080","article-title":"Characteristics of patients with relapsed\/refractory Burkitt non-Hodgkin lymphoma (NHL): impact on the feasibility of CAR-T cell therapy [abstract]","volume":"134","author":"Fortin Gamero","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025111014270114900_bib5","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1182\/blood-2021-146036","article-title":"Outcomes in relapsed\/refractory Burkitt lymphoma: a multi-centre Canadian experience [abstract]","volume":"138","author":"Manji","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2025111014270114900_bib6","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00277-017-3044-4","article-title":"In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study","volume":"96","author":"Cremer","year":"2017","journal-title":"Ann Hematol"},{"issue":"15","key":"2025111014270114900_bib7","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2025111014270114900_bib8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/PAS.0000000000000234","article-title":"Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases","volume":"38","author":"Morscio","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"21","key":"2025111014270114900_bib9","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"2025111014270114900_bib10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1309\/AJCPFUR1BK0UODTS","article-title":"Plasmablastic lymphomas with MYC\/IgH rearrangement: report of three cases and review of the literature","volume":"132","author":"Bogusz","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2025111014270114900_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bjh.18399","article-title":"Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia","volume":"199","author":"Jessa","year":"2022","journal-title":"Br J Haematol"},{"issue":"12","key":"2025111014270114900_bib12","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2025111014270114900_bib13","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1182\/bloodadvances.2023009731","article-title":"High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study","volume":"7","author":"Zayac","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2025111014270114900_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"2025111014270114900_bib15","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1158\/1078-0432.CCR-14-1019","article-title":"A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies","volume":"20","author":"Pardee","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2025111014270114900_bib16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00109-011-0785-8","article-title":"Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo","volume":"89","author":"Zachar","year":"2011","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"2025111014270114900_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2049-3002-2-4","article-title":"A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process","volume":"2","author":"Stuart","year":"2014","journal-title":"Cancer Metab"},{"key":"2025111014270114900_bib18","unstructured":"The ASCO Post\n          . FDA grants orphan drug designation to CPI-613 for treatment of Burkitt lymphoma. Updated 11 July 2018. Accessed 16 November 2023. https:\/\/ascopost.com\/News\/59041."},{"issue":"suppl 1","key":"2025111014270114900_bib19","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1182\/blood-2021-153662","article-title":"Complete remission with devimistat (CPI-613) in refractory Burkitt lymphoma","volume":"138","author":"Nikolaenko","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025111014270114900_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"31","key":"2025111014270114900_bib21","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1200\/JCO.23.02659","article-title":"Devimistat (CPI-613) with modified fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) versus FFX for patients with metastatic adenocarcinoma of the pancreas: the phase III AVENGER 500 study","volume":"42","author":"Philip","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025111014270114900_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbmt.2012.11.016","article-title":"Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research","volume":"19","author":"Maramattom","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2025111014270114900_bib23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B-cell antigen\u2013targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"2025111014270114900_bib24","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/blood.2024026831","article-title":"Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma","volume":"145","author":"Samples","year":"2025","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5556\/2418944\/blooda_adv-2025-016168-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5556\/2418944\/blooda_adv-2025-016168-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T19:27:11Z","timestamp":1762802831000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/21\/5556\/546236\/Novel-devimistat-results-in-complete-remissions-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":24,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016168","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,11]]},"published":{"date-parts":[[2025,10,31]]}}}